Clinical Trials Sponsored by Forest Laboratories

Total 9422 results

Forest Laboratories

Completed

Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

Helicobacter Infections

United Kingdom
Forest Laboratories

Completed

Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age

Infection

United States
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia (CAP)

Bacterial Pneumonia

United States, Russian Federation, Bulgaria, Germany, Poland, Romania, Ukraine, Argentina, Austria, Brazil, Estonia, France, Georgia, Hungary, India, Lithuania, Malaysia, Serbia, Slovakia, South Africa, Spain, Switzerland, Thailand
Forest Laboratories

Completed

A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021

Eosinophilic Esophagitis

United States
Forest Laboratories

Completed

Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia

Gastroparesis

Australia
Forest Laboratories

Completed

Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers

Healthy

United States
Forest Laboratories

Completed

Efficacy and Safety of Itopride vs Placebo in Heartburn

Heartburn

United States
Forest Laboratories

Completed

Effect of Azimilide Dihydrochloride on Renal Function

Healthy

United States
Forest Laboratories

Terminated

A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.

Coronary Artery Disease

United States
Forest Laboratories

Completed

A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures

Pain | Fissure in Ano
Forest Laboratories

Completed

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

Bipolar 1 Disorder

United States, Bulgaria, Croatia, India, Philippines, Romania, Russian Federation, Serbia, Turkey, Ukraine
Forest Laboratories

Completed

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

Bipolar I Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Finland, Germany, Romania, Russian Federation, Serbia, Ukraine
Forest Laboratories

Withdrawn

Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure

Anal Fissure

United States
Forest Laboratories

Terminated

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Estonia, Hungary, Iceland, Italy, Korea, Republic of, Serbia, Ukraine, Canada, Colombia, Belgium, France, New Zealand, Poland, South Africa, Spain
Forest Laboratories

Completed

Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo

Healthy

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Staphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia

United States
Forest Laboratories

Completed

Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital

Infections

United States
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Forest Laboratories

Completed

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Exocrine Pancreatic Insufficiency: Cystic Fibrosis

United Kingdom, Italy, Belgium, Bulgaria, France, Germany, Poland
Forest Laboratories

Completed

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency

United States, Italy, Ukraine
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

Major Depressive Disorder

United States, Canada
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Hypertension

United States
Forest Laboratories

Terminated

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) (SHIELD-2)

Heart Diseases | Cardiovascular Diseases | Arrhythmias, Cardiac | Implantable Cardioverter Defibrillator

United States, Belgium, Canada, Czech Republic, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden
Forest Laboratories

Unknown

Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment

Hypertension

United States
Forest Laboratories

Completed

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Forest Laboratories

Completed

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Forest Laboratories

Completed

Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)

Stroke, Acute

United States, Austria, Australia, Canada, Finland, Germany, Netherlands, Spain
Forest Laboratories

Completed

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Schizophrenia

United States
Forest Laboratories

Completed

Nebivolol in Patients With Systolic Stage 2 Hypertension (NEB-MD-20)

Hypertension

United States
Forest Laboratories

Completed

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

Atrial Fibrillation

United States, Canada
Forest Laboratories

Completed

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

Hypertension

United States
Forest Laboratories

Completed

Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia

Fibromyalgia

United States
Forest Laboratories

Completed

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

Dementia of the Alzheimer's Type

United States, Argentina, Chile, Mexico
Forest Laboratories

Completed

A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy

Hypertension

United States
Forest Laboratories

Terminated

Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia

Fibromyalgia

United States
Forest Laboratories

Completed

Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients

Major Depressive Disorder

United States
Forest Laboratories

Completed

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

Alzheimer's Disease

United States
Forest Laboratories

Completed

Study of Milnacipran for the Treatment of Fibromyalgia

Fibromyalgia

United States
Forest Laboratories

Completed

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Hypertension

United States
Forest Laboratories

Completed

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, Canada
Forest Laboratories

Completed

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (VLZ-MD-05)

Generalized Anxiety Disorder

United States
Forest Laboratories

Completed

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Diafert for Embryo Selection and Fertility Improvement (DESTINy) (DESTINy)

Infertility

Hungary
Forest Laboratories

Terminated

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Neoplasms | Febrile Neutropenia

United States
Forest Laboratories

Completed

PR-018: An Open-Label, Safety Extension of Study PR-011

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Forest Laboratories

Completed

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency | Pancreatectomy

Canada, United States, Poland, Slovakia

3

Subscribe